The Effectiveness of Intravitreal Avastin Injection for CRVO
1 other identifier
observational
68
1 country
1
Brief Summary
to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 29, 2012
CompletedFirst Posted
Study publicly available on registry
September 3, 2012
CompletedSeptember 3, 2012
August 1, 2012
August 29, 2012
August 29, 2012
Conditions
Eligibility Criteria
patients who suffer from CRVO and were injected by bevazicumab intravitrealy
You may qualify if:
- patients above 18 years old
- suffer from CRVO
- maximal visual acuity 6/15
You may not qualify if:
- VA of LP
- retinal disease other than CRVO
- incomplete medical record
- follow up less than 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ziv Hospitallead
Study Sites (1)
Ziv Medical Center
Safed, 13100, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 29, 2012
First Posted
September 3, 2012
Study Start
January 1, 2006
Last Updated
September 3, 2012
Record last verified: 2012-08